以下文章来源于内分泌早知道 ，作者关注内分泌的 内分泌早知道 . 深度分享内分泌用药经验、病例剖析、指南专业解读并紧跟国内外内分泌领域前沿进展。 许多糖尿病患者确诊初期常感到无所适从，不知如何有效管理病情。事实上，糖尿病并非不可控制，关键在于学会监测身体的关键信 号，并采取科学干预措施。通过长期稳定管理核心健康指标，不仅能维持血糖平稳，更能显著降低并发症风险，保障生活质量。 本文将系统介绍糖尿病患者日常必须关注的12项健康指标，涵盖血糖、血压、血脂等多个维度。这些指标并非难以监测，大多数可通过 家庭自测或定期体检获取数据。 了解并掌握这些关键数据的变化规律，有助于及时调整治疗方案，避免病情恶化。从糖化血红蛋白到尿微量白蛋白，从体重指数到足部 神经检查，每一项指标都对应着不同的健康风险点。科学认知这些数据背后的意义，才能实现精准控糖，真正远离糖尿病并发症的威 胁。 空腹血糖（4.4- 7.0mmol/L）反映基础代谢状态，超过7.0mmol/L提示需调整夜间控糖策略。餐后血糖（7.8- 10.0mmol/L）直接体现 饮食管理效果，持续偏高需优化碳水化合物摄入。糖化血红蛋白（＜7.0%）作为血糖控制的"金标准" ...

Core Viewpoint - Medtronic is strategically establishing a Global Capability Centre in Pune, India, to support its diabetes business spin-off, MiniMed, reflecting a focus on global resource allocation and innovation service models [1][6][20]. Group 1: Global Capability Centre in Pune - The Pune centre is expected to create 300 jobs in its first year, expanding to 600 over four years, and will serve as an "excellence operations platform" integrating technology and customer support for global diabetes operations [3][11]. - The centre's establishment is part of a systematic approach to support MiniMed's global operational framework, indicating a proactive strategy rather than a defensive measure [8][20]. Group 2: MiniMed's Formation and Strategy - Medtronic plans to complete the spin-off of its diabetes business into MiniMed within 18 months, with an IPO for up to 20% of shares, while the remaining will be distributed to existing shareholders [6][12]. - MiniMed will focus on developing a comprehensive insulin management ecosystem, including automated insulin delivery systems and smart multi-dose injection solutions [13][16]. Group 3: Market Potential and Local Advantages - India has the second-largest number of diabetes patients globally, with projections indicating over 100 million diagnosed by 2025, and the diabetes care market is expected to grow from ₹1.25 trillion in 2024 to ₹1.87 trillion by 2030, at a CAGR of nearly 8% [9][11]. - Pune's local talent pool and digital infrastructure make it an ideal location for Medtronic's new centre, enhancing its capabilities in remote healthcare and AI [11]. Group 4: Competitive Landscape - MiniMed faces increasing competition from companies like Tandem Diabetes Care and Beta Bionics, which are advancing in wearable pump design and smart feedback algorithms [19]. - The success of MiniMed will depend on its ability to quickly translate the digital capabilities from the Pune centre into product upgrades to maintain competitiveness in the market [19]. Group 5: Conclusion - The establishment of the Pune centre is a strategic move for Medtronic to enhance its operational capabilities and profitability while transitioning MiniMed into a solution provider in the diabetes management space [20].

21世纪经济报道记者季媛媛 上海报道 中国庞大的糖尿病患者群体为颠覆性的持续葡萄糖监测（CGM）技术提供了广阔的市场潜力。目前， 中国糖尿病患者已超1.4亿，居世界第一，预计2045年将增加到1.74亿。糖尿病并发症不仅可导致失明、 肾衰竭，还会增加冠心病和脑卒中风险1.5-2.5倍。 巨大的市场需求推动了该市场的激烈竞争，吸引了众多参与者的加入。有券商医药行业分析师对21世纪 经济报道记者表示，目前国内市场的CGM产品主要分为两大阵营，第一个阵营主要以雅培、德康等进 口企业为主，其产品凭借用户体验性、性价比、品牌黏度、市场规模等优势占据CGM市场主导地位； 第二阵营主要以九诺、凯立特、移宇科技、微泰、硅基等国产厂商为主，它们的产品在软件技术上具有 一定的优势，性能接近进口品牌，它们希望通过降低成本、实施差异化策略、抢占医院渠道、提升研发 至生产的稳定性以及增强批量生产的能力，与雅培等跨国企业竞争市场份额。 "在雅培2017年进入中国之前，国内CGM产品已经销售了十几年，但是一直难以打开市场，整个市场销 售额都仅有千万规模。实际上，这些问题与产品本身息息相关，如技术薄弱、用户黏性不足、价格偏 高，这些都限制了 ...

Insulet (PODD) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation First Quarter Earnings Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, June Lazaroff, Senior Director, Investor Relations. Good afternoon, ...

Core Viewpoint - The company emphasizes its commitment to innovation and sustainable growth in the diabetes management sector, despite recent stock price fluctuations and market challenges [1][4][5]. Financial Performance - In 2024, the company achieved a revenue of 4.44 billion yuan, a year-on-year increase of 9.47%, and a net profit attributable to shareholders of 326.29 million yuan, up 14.73% [1]. - In Q1 2025, the company reported a revenue of 1.04 billion yuan, a 2.76% increase year-on-year, but a net profit of 72.12 million yuan, down 10.90% compared to the previous year [1][8]. Industry Outlook - The global adult diabetes patient population is projected to reach 853 million by 2050, with China accounting for approximately 148 million patients in 2024, representing 25% of the global total [1]. - The demand for blood glucose monitoring products is expected to rise significantly due to the aging population and increasing health management awareness in developing countries [1][2]. Product Development and Strategy - The company is focused on building a comprehensive diabetes management ecosystem through innovative products like Continuous Glucose Monitoring (CGM) systems and partnerships with healthcare institutions [2][3]. - The CGM product line is a strategic focus for the company, with expected revenues of 200-300 million yuan in 2024 [3][4]. Market Position and Competition - The domestic CGM market is experiencing rapid growth, with the company actively expanding its market share and optimizing its product offerings [6][7]. - The company is committed to maintaining its leadership position in the diabetes monitoring sector through continuous innovation and service enhancement [6][7]. Shareholder Engagement - The company has implemented multiple share repurchase plans to enhance shareholder value and market confidence, with a total repurchase amounting to approximately 64.1 million yuan as of April 30, 2025 [1][4][5]. - The management acknowledges the importance of investor communication and aims to improve transparency and information disclosure [1][4].